...
首页> 外文期刊>European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology >Functional mechanism of ASP5736, a selective serotonin 5-HT5A receptor antagonist with potential utility for the treatment of cognitive dysfunction in schizophrenia
【24h】

Functional mechanism of ASP5736, a selective serotonin 5-HT5A receptor antagonist with potential utility for the treatment of cognitive dysfunction in schizophrenia

机译:ASP5736的功能机制,一种选择性血清素5-HT5A受体拮抗剂,具有潜在效用,用于治疗精神分裂症中的认知功能障碍

获取原文
获取原文并翻译 | 示例
           

摘要

The 5-HT5A receptor is arguably the least understood 5-HT receptor. Despite widespread expression in human and rodent brains it lacks specific ligands. Our previous results suggest that 5-HT5A receptor antagonists may be effective against cognitive impairment in schizophrenia. In this study, using behavioral, immunohistochemical, electrophysiological and microdialysis techniques, we examined the mechanism by which ASP5736, a novel and selective 5-HT5A receptor antagonist, exerts a positive effect in animal models of cognitive impairment. We first confirmed the effect of ASP5736 on cognitive deficits in rats treated subchronically with phencyclidine hydrochloride (PCP) using an attentional set shifting task. Subsequently, we identified 5-HT5A receptors in dopaminergic (DAergic) neurons and parvalbumin (PV)-positive interneurons in the ventral tegmental area (VTA) and in PV-positive interneurons in the medial prefrontal cortex (mPFC). Burst firing of the DAergic cells in the parabrachial pigmental nucleus (PBP) in the VTA, which predominantly project to the mPFC, was significantly enhanced by treatment with ASP5736. In contrast, ASP5736 exerted no significant effect on either the firing rate or burst firing in the DA cells in the paranigral nucleus (PN), that project to the nucleus accumbens (N. Acc.). ASP5736 increased the release of DA and gamma-aminobutyric acid (GABA) in the mPFC of subchronically PCP-treated rats. These results support our hypothesis that ASP5736 might block the inhibitory 5-HT5A receptors on DAergic neurons in the VTA that project to the mPFC, and interneurons in the mPFC, and thereby improve cognitive impairment by preferentially enhancing DAergic and GABAergic neurons in the mPFC. (C) 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/hcenses/by-nc-nd/4.0/).
机译:5-HT5A受体可以是最不理解的5-HT受体。尽管人和啮齿动物的大脑中普遍表达,但它缺乏特定的配体。我们以前的结果表明,5-HT5A受体拮抗剂可能对精神分裂症中的认知障碍有效。在本研究中,使用行为,免疫组织化学,电生理学和微透析技术,我们研究了ASP5736,一种新颖和选择性5-HT5A受体拮抗剂的机制在认知障碍的动物模型中发挥积极作用。我们首先使用注意力集转换任务与盐酸相邻盐酸盐(PCP)与邻接邻接治疗的大鼠的认知缺陷对ASP5736对大鼠的认知缺陷的影响。随后,我们鉴定了多巴胺能(DARICIC)神经元(DAIRIC)神经元和旁阳白蛋白(PV)的5-HT5A受体,在腹侧引物区域(VTA)和中间前额叶皮质(MPFC)中的PV阳性间核中。通过ASP5736治疗显着提高了VTA中PARABRARIAL颜料核(PBP)中的DAIRICIC细胞的突发烧制,这主要是通过ASP5736治疗而显着提高。相反,ASP5736对突出核(PN)中的DA细胞中的烧制率或突发烧制没有显着影响,该突出核(PN)突出(N.CHAC。)。 ASP5736增加了诸如邻泊PCP处理大鼠的MPFC中的DA和γ-氨基丁酸(GABA)的释放。这些结果支持我们的假设,即ASP5736可能阻断在VTA中抑制5-HT5A受体,该VTA在突出的VTA中的晚期神经元,以及MPFC中的中间核来,从而通过优先增强MPFC中的晚期和加巴生物神经元来改善认知障碍。 (c)2018作者。由elsevier b.v发布。这是CC By-NC-ND许可下的开放式访问文章(http://creativecommons.org/hcenses/by-nc-nd/4.0/)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号